Spatial Genomics Market Analysis: Growth Drivers and Opportunities

-

The global spatial genomics and transcriptomics market is projected to reach USD 800 million by 2027 from USD 355 million in 2022, at a CAGR of 17.6% during the forecast period. Market growth is largely driven by the increasing development in the area such as neurodegenerative diseases and cancer. Along with this, launch of several advanced products are contributing towards the growth of the market. On the other hand, need of high initial investments, and dearth of skilled professionals are some factors limiting the market growth.

The market for spatial genomics & transcriptomics is highly consolidated, with key players strategizing to capture the market. Prominent players in the market are NanoString Technologies, Inc. (US), 10X Genomics (US), Illumina (US), Bio-Rad Laboratories (US), Bio-Techne Corporation (US), Standard BioTools Inc. (US), Genomic Vision SA (France), Akoya Biosciences, Inc. (US), Danaher Corporation (US), Natera, Inc. (US), PerkinElmer, Inc. (US), Seven Bridges Genomics (US), S2 Genomics, Inc. (US), Cantata Bio (US), Vizgen Corporation (US), BioSpyder Technologies Inc. (US), Optical Biosystems Inc. (US), Miltenyi Biotec (Germany), Ultivue Inc. (US), Lunaphore Technologies SA (Switzerland), Rebus Biosystems LLC (US), Resolve Biosciences (Germany), Singular Genomics, Inc. (US), and Veracyte (US).

NanoString Technologies, Inc. (US)

NanoString provides life science tools for translational research. The company is engaged in developing, manufacturing, and commercializing instruments, consumables, and services for simultaneously profiling gene and protein activity from a single tissue sample. In 2019, the company launched the GeoMx Digital Spatial Profiler, enabling highly multiplexed spatial profiling of RNA and protein targets in various sample types, including FFPE tissue sections. The company operates in the spatial genomics and transcriptomics market through its Product segment.

NanoString achieved its 1,000th placement of the nCounter in 2020; the installed base for Chromium reached 1,105 by Q3 of 2022. Similarly, the company achieved robust placements for its GeoMx Digital Spatial profiler (DSP) systems. The installed base for GeoMx jumped to 255 units in 2021 from 130 units in 2020, showcasing its strength in the instruments business. In February 2021, NanoString launched Whole Transcriptome Atlases, which drove a steady increase in the demand for GeoMx consumables since its launch at the Third Annual Spatial Genomics Summit.

10X Genomics (US)

10x Genomics accounted for the second-largest share in the global spatial genomics and transcriptomics market in 2021. 10x Genomics offers the Visium Spatial platform and consumables such as Visium Spatial Gene Expression assays and Visium mRNA arrays to measure spatial gene expression patterns using high-density DNA barcode sequencing arrays. The company acquired Spatial Transcriptomics (Sweden) in 2018 and entered the spatial genomics and transcriptomics market. Its unique position and leadership in single-cell analysis have paved the way for developing spatial technologies. While the company does not offer spatial transcriptomic solutions at the single-cell level, its expertise offers 10x Genomics a competitive edge in the market.

DRIVER: Increasing adoption of spatial genomics & transcriptomics in drug discovery & development

In recent years, spatial genomics and transcriptomics have shifted from strictly research applications to drug discovery & development applications. Genomics and transcriptomics are major tools for accelerating drug discovery & development processes. Spatial techniques are presently in use to enhance the understanding of infectious diseases. Applications of spatial genomics & transcriptomics are expanding with time, targeted towards generating insights into neurodegenerative diseases and cancer. Spatial genomics and transcriptomics is also anticipated to address the one of the current unmet clinical needs in the field of oncology, which is the need for predictive biomarkers of response. These biomarkers assist in developing immunotherapies by offering a greater understanding of the microenvironment of tumor.

Related News

https://www.marketsandmarkets.com/Market-Reports/spatial-genomics-transcriptomics-market-170900551.html

https://www.marketsandmarkets.com/PressReleases/spatial-genomics-transcriptomics.asp

https://www.marketsandmarkets.com/ResearchInsight/spatial-genomics-transcriptomics-market.asp

Comments

Post a Comment

Popular posts from this blog

Minimally Invasive Surgical Instruments Market Report, 2026

-
The global minimally invasive surgical instruments market is projected to reach USD 28.9 billion by 2026 from USD 20.2 billion in 2021, at a CAGR of 7.4% during the forecast period. Growth in this market is mainly driven by factors such as the increasing number of surgical procedures worldwide, the advantages of MIS over open surgical techniques, and the increasing adoption of advanced robotics in ASCs. However, the high degree of market consolidation among market players and the requirement of high capital investments are the major factors hampering the growth of this market. Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=682 The key players in this market are Medtronic plc (Ireland), Johnson Johnson (US), Stryker Corporation (US), Abbott Laboratories, Inc. (US), Boston Scientific Corporation (US), B. Braun Melsungen AG (Germany), CONMED Corporation (US), Smith Nephew plc (UK), Zimmer Biomet Holdings, Inc. (US), Becton, Dickinson and Comp...
Read more

Advancements Fueling Cardiac Monitoring Devices Market Growth

-
The global Cardiac Monitoring and Management Devices Market has been experiencing an upward surge, projected to reach an impressive USD 26.8 billion by 2025 from its valuation of USD 22.1 billion in 2020, with a steady Compound Annual Growth Rate (CAGR) of 4.0% from 2020 to 2025. This exponential growth can be attributed to several key factors that continue to shape and propel this industry forward. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=55 Factors Driving Cardiac Monitoring Devices Market Growth Rising Cardiovascular Disease Prevalence: The prevalence of cardiovascular diseases (CVD) is on the rise globally, driving the demand for advanced cardiac monitoring devices. This trend is a significant catalyst for the market's growth trajectory. Innovative Product Launches: Market players have been proactive in introducing innovative products, leveraging advanced technologies. These advancements include improved algorithms, simplified...
Read more

Antimicrobial Susceptibility Testing Market : Emerging Market Trends, Top Growing Segments and Future Trends

-
Growth in this  antimicrobial susceptibility testing market is primarily driven by the rising incidence of infectious diseases; technological advancements towards the development of rapid AST technologies; increased funding, research grants, and public-private investments; growing government initiatives to detect and control antimicrobial-resistant species; and the emergence of multidrug resistance due to drug abuse. However, the high cost of automated antimicrobial susceptibility testing systems is expected to limit market growth in the coming years. Complex regulatory frameworks that delay the approval of new microbial susceptibility tests are also expected to challenge market growth to a certain extent. According to research report the global antimicrobial susceptibility testing market size is projected to reach USD 4.2 billion by 2025 from USD 3.2 billion in 2020, at a CAGR of 5.5% during the forecast period. Download PDF Brochure: https://www.marketsandmarkets.c...
Read more